Products for Research Use Only

Ripretinib (Standard)

CAT: 0804-HY-112306R-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-112306R-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Ripretinib (Standard) is the analytical standard of Ripretinib. This product is intended for research and analytical applications. Ripretinib (DCC-2618) is an orally bioavailable, selective KIT and PDGFRA switch-control inhibitor. Ripretinib (DCC-2618) targets and binds to both wild-type and mutant forms of KIT and PDGFRA specifically at their switch pocket binding sites, thereby preventing the switch from inactive to active conformations of these kinases and inactivating their wild-type and mutant forms. Ripretinib (DCC-2618) also inhibits multiple other kinase targets, such as FLT3 and KDR (or VEGFR-2) [1][2]. DCC-2618 exerts antineoplastic effect and induces apoptosis[3].
CAS Number
1442472-39-0
UNSPSC
12352100
Target
Apoptosis; c-Kit; FLT3; PDGFR; Reference Standards; VEGFR
Related Pathways
Apoptosis; Others; Protein Tyrosine Kinase/RTK
Field of Research
Cancer
Smiles
O=C(NC1=CC(C2=CC3=C(C=C(NC)N=C3)N(CC)C2=O)=C(Br)C=C1F)NC4=CC=CC=C4
Molecular Formula
C24H21BrFN5O2
Molecular Weight
510.36
References & Citations
[1]KIT/PDGFR Inhibitor DCC-2618.|[2]BLU-285, DCC-2618 Show Activity against GIST. Cancer Discov. 2017 Feb;7 (2) :121-122.|[3]Schneeweiss M, et al. The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis. Haematologica. 2018 May;103 (5) :799-809.
Shipping Conditions
Room temperature
Scientific Category
Reference Standards